Tvardi Therapeutics, Inc.
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
TVRD | IL
Overview
Corporate Details
- ISIN(s):
- US1407553072
- LEI:
- 549300COVOY41P0GZ881
- Country:
- United States of America
- Address:
- 3 SUGAR CREEK CTR. BLVD., 77478 SUGAR LAND
- Website:
- https://tvarditherapeutics.com
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies. The company's core technology targets STAT3 (Signal Transducer and Activator of Transcription 3), a key regulatory protein implicated in the progression of various diseases. Tvardi is advancing a pipeline of STAT3 inhibitors to treat conditions with significant unmet medical needs, primarily focusing on fibrosis-driven diseases and diverse cancers.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Tvardi Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Tvardi Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Tvardi Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
%20LTD/other/Cuprina_Holdings_Cayman_LTD-logo.png){kind=logo}
